A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2006
Since a proportion of patients with Acute Viral Hepatitis-B develop severe hepatitis and fulminant hepatic failure, it is logical to believe that a rapid reduction in the HBV DNA levels by using antiviral agents could result in a less intense host response against the hepatitis B virus. However, the experience with lamivudine treatment of immunocompetent patients with AVH-B is limited.The aim of the present study was to evaluate the efficacy, utility and safety of lamivudine in treating immunocompetent patients with AVH-B.
Epistemonikos ID: 794d12cddd1fd8d19479c48c7fedbc6fc5bfe03d
First added on: Nov 24, 2021